0001474064-13-000064.txt : 20130410
0001474064-13-000064.hdr.sgml : 20130410
20130410181930
ACCESSION NUMBER: 0001474064-13-000064
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20130408
FILED AS OF DATE: 20130410
DATE AS OF CHANGE: 20130410
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Nader Francois
CENTRAL INDEX KEY: 0001365343
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 000-23272
FILM NUMBER: 13754651
MAIL ADDRESS:
STREET 1: 550 HILLS DRIVE
CITY: BEDMINSTER
STATE: NJ
ZIP: 07921
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: NPS PHARMACEUTICALS INC
CENTRAL INDEX KEY: 0000890465
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 870439579
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 550 HILLS DRIVE
CITY: BEDMINSTER
STATE: NJ
ZIP: 07921
BUSINESS PHONE: (908) 450-5300
MAIL ADDRESS:
STREET 1: 550 HILLS DRIVE
CITY: BEDMINSTER
STATE: NJ
ZIP: 07921
4
1
edgar.xml
PRIMARY DOCUMENT
X0306
4
2013-04-08
0000890465
NPS PHARMACEUTICALS INC
NPSP
0001365343
Nader Francois
550 HILLS DRIVE
BEDMINSTER
NJ
07921
1
1
0
0
President, CEO and Director
Common Stock
2013-04-08
4
M
0
35644
5.73
A
272504
D
Common Stock
2013-04-08
4
M
0
7632
4.07
A
280136
D
Common Stock
2013-04-08
4
M
0
7100
4.50
A
287236
D
Common Stock
2013-04-08
4
M
0
6567
4.37
A
293803
D
Common Stock
2013-04-08
4
M
0
6104
4.31
A
299907
D
Common Stock
2013-04-08
4
M
0
55470
4.13
A
355377
D
Common Stock
2013-04-08
4
M
0
16125
4.42
A
371502
D
Common Stock
2013-04-08
4
M
0
15358
4.29
A
386860
D
Common Stock
2013-04-08
4
S
0
150000
11.0053
D
236860
D
Common Stock
2013-04-09
4
M
0
79356
4.29
A
316216
D
Common Stock
2013-04-09
4
M
0
15000
4.10
A
331216
D
Common Stock
2013-04-09
4
M
0
13875
3.93
A
345091
D
Common Stock
2013-04-09
4
M
0
41769
3.85
A
386860
D
Common Stock
2013-04-09
4
S
0
150000
11.2656
D
236860
D
Common Stock
2013-04-10
4
M
0
58231
3.85
A
295091
D
Common Stock
2013-04-10
4
M
0
16754
3.60
A
311845
D
Common Stock
2013-04-10
4
M
0
54000
3.34
A
365845
D
Common Stock
2013-04-10
4
S
0
148367
11.6773
D
217478
D
Stock Option
5.73
2013-04-08
4
M
0
35644
0
D
2016-06-05
Common Stock
35644
64356
D
Stock Option
4.07
2013-04-08
4
M
0
7632
0
D
2016-07-17
Common Stock
7632
1243
D
Stock Option
4.50
2013-04-08
4
M
0
7100
0
D
2016-10-16
Common Stock
7100
1775
D
Stock Option
4.37
2013-04-08
4
M
0
6567
0
D
2017-01-16
Common Stock
6567
2308
D
Stock Option
4.31
2013-04-08
4
M
0
6104
0
D
2017-04-16
Common Stock
6104
2771
D
Stock Option
4.13
2013-04-08
4
M
0
55470
0
D
2017-07-02
Common Stock
55470
9030
D
Stock Option
4.42
2013-04-08
4
M
0
16125
0
D
2017-07-16
Common Stock
16125
2625
D
Stock Option
4.29
2013-04-08
4
M
0
15358
0
D
2017-09-10
Common Stock
15358
79356
D
Stock Option
4.29
2013-04-09
4
M
0
79356
0
D
2017-09-10
Common Stock
79356
0
D
Stock Option
4.10
2013-04-09
4
M
0
15000
0
D
2017-10-15
Common Stock
15000
3750
D
Stock Option
3.93
2013-04-09
4
M
0
13875
0
D
2018-01-15
Common Stock
13875
4875
D
Stock Option
3.85
2013-04-09
4
M
0
41769
0
D
2018-03-17
Common Stock
41769
58231
D
Stock Option
3.85
2013-04-10
4
M
0
58231
0
D
2018-03-17
Common Stock
58231
0
D
Stock Option
3.60
2013-04-10
4
M
0
16754
0
D
2018-04-15
Common Stock
16754
5746
D
Stock Option
3.34
2013-04-10
4
M
0
54000
0
D
2020-02-19
Common Stock
54000
54000
D
The shares were sold pursuant to a predefined price target in a trading plan qualified under Rule 10b5-1 of the Securities Exchange Act of 1934, as amended, that was effective November 28, 2012.
Includes 734 shares of stock obtained through Issuer's Employee Stock Purchase Plan on 3/31/13.
The price shown above represents the weighted average price of the shares sold. The range of sales prices was 11.00 and 11.04. The Reporting Person will provide to the Issuer, any security holder of the Issuer, or the SEC Staff, upon request, information regarding the number of shares sold at each price within the range of prices actually paid.
The price shown above represents the weighted average price of the shares sold. The range of sales prices was 11.25 and 11.39. The Reporting Person will provide to the Issuer, any security holder of the Issuer, or the SEC Staff, upon request, information regarding the number of shares sold at each price within the range of prices actually paid.
The price shown above represents the weighted average price of the shares sold. The range of sales prices was 11.65 and 11.71. The Reporting Person will provide to the Issuer, any security holder of the Issuer, or the SEC Staff, upon request, information regarding the number of shares sold at each price within the range of prices actually paid.
On June 5, 2006, the Reporting Person received a grant of 100,000 stock options under the Issuer's 2005 Omnibus Incentive Plan. The options become exercisable based on the following vesting schedule: 28% on the first anniversary of the date of grant and 2% each month for the next three years.
On July 17, 2006, the Reporting Person received a grant of 8,875 stock options under the Issuer's 2005 Omnibus Incentive Plan. The options become exercisable based on the following vesting schedule: 28% on the first anniversary of the date of grant and 2% each month for the next three years.
On October 16, 2006, the Reporting Person received a grant of 8,875 stock options under the Issuer's 1998 Stock Incentive Plan. The options become exercisable based on the following vesting schedule: 28% on the first anniversary of the date of grant and 2% each month for the next three years.
On January 16, 2007, the Reporting Person received a grant of 8,875 stock options under the Issuer's 1998 Stock Incentive Plan. The options become exercisable based on the following vesting schedule: 28% on the first anniversary of the date of grant and 2% each month for the next three years.
On April 16, 2007, the Reporting Person received a grant of 8,875 stock options under the Issuer's 1998 Stock Incentive Plan. The options become exercisable based on the following vesting schedule: 28% on the first anniversary of the date of grant and 2% each month for the next three years.
On July 2, 2007, the Reporting Person received a grant of 64,500 stock options under the Issuer's 1998 Stock Incentive Plan. The options become exercisable based on the following vesting schedule: 28% on the first anniversary of the date of grant and 2% each month for the next three years.
On July 16, 2007, the Reporting Person received a grant of 18,750 stock options under the Issuer's 1998 Stock Incentive Plan. The options become exercisable based on the following vesting schedule: 28% on the first anniversary of the date of grant and 2% each month for the next three years.
On September 10, 2007, the Reporting Person received a grant of 94,714 stock options under the Issuer's 1998 Stock Incentive Plan. The options become exercisable based on the following vesting schedule: 25% on the first anniversary of the date of grant, 25% on the second anniversary of the date of grant, and 50% on the third anniversary of the date of grant.
On October 15, 2007, the Reporting Person received a grant of 18,750 stock options under the Issuer's 1998 Stock Incentive Plan. The options become exercisable based on the following vesting schedule: 28% on the first anniversary of the date of grant and 2% each month for the next three years.
On January 15, 2008, the Reporting Person received a grant of 18,750 stock options under the Issuer's 1998 Stock Incentive Plan. The options become exercisable based on the following vesting schedule: 28% on the first anniversary of the date of grant and 2% each month for the next three years.
On March 17, 2008, the Reporting Person received a grant of 100,000 stock options under the Issuer's 1998 Stock Incentive Plan. The options become exercisable based on the following vesting schedule: 28% on the first anniversary of the date of grant and 2% each month for the next three years.
On April 15, 2008, the Reporting Person received a grant of 22,500 stock options under the Issuer's 1998 Stock Incentive Plan. The options become exercisable based on the following vesting schedule: 28% on the first anniversary of the date of grant and 2% each month for the next three years.
On February 19, 2010, the Reporting Person was granted options to purchase shares of Common Stock under the Issuer's 2005 Omnibus Incentive Plan, which are subject to both performance conditions and time-based vesting. On December 21, 2012, the performance criteria for 54,000 of these options was satisfied when the FDA unanimously voted to approve the NDA for GATTEX for the treatment of SBS. These options will vest and become exercisable based on the following vesting schedule: 25% on each of the first four anniversaries of the date of grant.
/s/ Francois Nader, by Edward Stratemeier as Attorney-in-Fact
2013-04-10